Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

PurMinds believes psychedelics hold promise for neurological conditions

In an increasingly competitive field, PurMinds is focusing on exploring psychedelics' potential to treat neurodegenerative disorders.

By Brian Buntz | August 6, 2021

PurMindsPurMinds believes psychedelics hold promise for neurological conditions

Interest in psychedelics has ratched up in recent years and a growing number of drug companies are beginning to explore their potential to treat everything from depression to neurodegeneration.

“It is a really really exciting time,” said Aron Buchman, chief strategy officer, PurMinds BioPharma, which is exploring psychedelics’ potential to treat neurological diseases.

American author Michael Pollan recently surmised in an interview with Independent that the psychedelics industry was in a “gold rush” phase. “Whether it’s going to work is another question. I think it’s going to be very challenging to fit into the system,” Pollan added.

Headquartered in North York, Ontario, PurMinds is based in a country that is warming up to the therapeutic potential of psychedelics. The Canadian government has granted a number of patients a federal dispensation covering the therapeutic use of psychedelics.

Canada was also “at the forefront of the whole cannabis initiative,” Buchman said. Canada legalized cannabis in 2018, initiating a transition from a deregulated environment concerning the plant to a regulated one.

There are lessons to draw from that transition, Buchman said, but adds that “psychedelics is a completely different field.”

Compared with cannabis, psychedelics arguably up the stakes in terms of their potential therapeutic potential and pitfalls. In the positive column, they promise to treat disorders ranging from addiction to chronic pain to PTSD and depression. But a laissez-faire approach to psychedelic regulation comes with toxicity risks. Excessive doses of psilocybin, however, can lead to proverbial “bad trips,” vomiting and even more significant problems such as seizures or coma.

Maximizing the benefits of psychedelics depends on delivering precise doses of standardized psychedelic therapies, Buchman explained. PurMinds is thus focused on standardized and uniform compounds.

When developing therapeutic psychedelics, it is vital to take “guesswork” out of the equation. “We really support stable pharma-grade compounds that are research-and-development oriented,” Buchman said.

PurMinds has decided to focus on neurological applications of psychedelics given the high unmet need in the field. “We feel that we’ll find at least a glimmer of hope in addressing neurodegenerative disorders, whether it’s Alzheimer’s or Parkinson’s,” Buchman said. “I think that neurodegeneration, over the next 50 years, is going to become a huge, huge issue.”


Filed Under: clinical trials, Drug Discovery, Neurological Disease
Tagged With: Alzheimer’s, cannabis, depression, neurodegeneration, neurological conditions, Parkinson's, psychedelics, PTSD, PurMinds
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50